Chugai Seiyaku Kabushiki Kaisha

Chugai Pharmaceutical Co.

Kabushiki Kaisha Toshiba

Yoshiki Yamada

Masayuki Tsuchiya

Kouji Matsushima

Koh Sato

Tatsumi Yamazaki

Yoshihiro Matsumoto

Tatsuhiko Kodama

Kou-ichi Jishage

Tatsuya Kiyasu

Kazuyuki Tabata

Akihiro Kuzumaki

Mai Yamashiro

Nobuo Kamada

Takao Hamakubo

Bunshiro Yamaki

Ryoichi Saitoh

Kou-Ichi Jishage

The present invention provides a method of producing a recombinant antibody efficiently and at low cost. Disclosed is a method of producing an antibody or a fragment thereof, comprising allowing a cell to produce the antibody or the fragment, wherein the cell contains a larger number of copies of an exogenous DNA encoding the light chain or a fragment thereof of the antibody than the number of copies contained in the cell of an exogenous DNA encoding the heavy chain or a fragment thereof of the antibody. The present invention also provides a recombinant vector comprising one copy of a DNA encoding the heavy chain or a fragment thereof of an antibody and two or more copies of a DNA encoding the light chain or a fragment thereof of the antibody; and a transformant.

Composition comprising an antibody

Method for production of antibody

This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.

Methods for producing antibodies

Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced. Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.

Transgenic mice expressing baculovirus soluble GP64 and methods of using such mice to make antibodies

Methods for producing antibody

The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer.

Antibodies that inhibit transport activity of peptide transporters

A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

Reshaped human antibody to human interleukin-8

Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing

Recombinant materials for producing humanized anti-IL-8 antibodies

Method to treat inflammation with humanized anti-IL-8-antibodies

Polynucleotides which encode reshaped IL-8-specific antibodies and

According to a method of manufacturing a high-frequency bipolar transistor, a p-type base region is formed on an n-type silicon substrate. A first oxide film and a nitride film are formed on the base region. A base contact hole is formed by etching, and a first polysilicon film containing a p-type impurity and serving as a base electrode is formed thereon. A second oxide film having a thickness larger than that of the first oxide film is formed by thermal oxidation around the base contact hole to surround the first polysilicon film. A portion of the nitride film which is not covered with said second oxide film and a portion of the first oxide film therebelow are removed by etching to form an emitter contact hole. A second polysilicon film including an n-type impurity and serving as an emitter electrode is formed in the emitter contact hole. The n-type impurity in the second polysilicon film is diffused in the substrate by annealing to form an n-type emitter region. In the completed bipolar transistor, the base electrode and the emitter electrode are insulated from each other by the second oxide film.

Method of manufacturing semiconductor device

Growing community of inventors

Tokyo, Japan

Yoshiki Yamada